至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Immunogenic Properties of MVs Containing Structural Hantaviral Proteins: An Original Study

Pharmaceutics. 2022-01; 
Layaly Shkair, Ekaterina Evgenevna Garanina, Ekaterina Vladimirovna Martynova, Alena Igorevna Kolesnikova, Svetlana Sergeevna Arkhipova, Angelina Andreevna Titova, Albert Anatolevich Rizvanov, Svetlana Francevna Khaiboullina
Products/Services Used Details Operation
Plasmid DNA Preparation Plasmid vectors pLX-PUUV-S and pLX-Katushka2S were previously generated using Gateway cloning technology, while pWPT-PUUV-M was subcloned by GenScript (GenScript, Jiangsu, China) Get A Quote
PCR Cloning and Subcloning Get A Quote

摘要

Hemorrhagic fever with renal syndrome (HFRS) is an emerging infectious disease that remains a global public health threat. The highest incidence rate is among zoonotic disease cases in Russia. Most cases of HFRS are reported in the Volga region of Russia, which commonly identifies the Puumala virus (PUUV) as a pathogen. HFRS management is especially challenging due to the lack of specific treatments and vaccines. This study aims to develop new approaches for HFRS prevention. Our goal is to test the efficacy of microvesicles (MVs) as PUUV nucleocapsid (N) and glycoproteins (Gn/Gc) delivery vehicles. Our findings show that MVs could deliver the PUUV N and Gn/Gc proteins in vitro. We have also demonstrated that MV... More

关键词

delivery system, hemorrhagic fever with renal syndrome, microvesicles, orthohantavirus, vaccine